具有抗结核分枝杆菌潜在活性的脂质基纳米复合材料的策略:微生物耐药性挑战和药物递送趋势

Q2 Pharmacology, Toxicology and Pharmaceutics OpenNano Pub Date : 2023-09-01 DOI:10.1016/j.onano.2023.100171
Arthur Cavalcante Hatae , Cesar Augusto Roque-Borda , Fernando Rogério Pavan
{"title":"具有抗结核分枝杆菌潜在活性的脂质基纳米复合材料的策略:微生物耐药性挑战和药物递送趋势","authors":"Arthur Cavalcante Hatae ,&nbsp;Cesar Augusto Roque-Borda ,&nbsp;Fernando Rogério Pavan","doi":"10.1016/j.onano.2023.100171","DOIUrl":null,"url":null,"abstract":"<div><p><em>Mycobacterium tuberculosis</em> (MTB), the causative agent of tuberculosis, stands as an immensely devastating and persistently relevant pathogen, claiming the lives of millions each year. This infectious bacterium remains a formidable global health challenge, necessitating urgent attention and comprehensive strategies to combat its profound impact on public health. MTB is a finicky bacterium that manages to sneak into macrophages and fibroblasts to avoid being eliminated. Current first-line treatments allow the control of the spread of an active MTB, but are not capable of effectively controlling when MTB is in its latent phase and struggle against MTB resistant strains. Lipid-based nanoparticles have gained significant attention in the field of tuberculosis nanotechnology treatments, owing to their compelling logical underpinnings, remarkable merits, and acknowledged demerits. These nanoparticles offer a rational approach by harnessing the unique properties of lipids, such as biocompatibility and stability, to encapsulate and protect anti-tuberculosis drugs. Their inherent ability to actively target infected macrophages holds immense promise for precise drug delivery to the infection site, enhancing therapeutic efficacy. However, it is crucial to consider potential limitations, such as the restricted payload capacity due to their small size and challenges in achieving sustained drug release. Despite these challenges, lipid-based nanotechnology represents an exciting frontier for combating drug resistance and advancing tuberculosis treatment strategies, warranting further exploration and development in this field. In addition, we emphasize the characteristics of lipid-based nanoparticles with the ability to improve the administration, stability, and dosage of these molecules. New modified systems are expected to be successful in the coming years as nanotechnology has improved various treatments in other diseases.</p></div>","PeriodicalId":37785,"journal":{"name":"OpenNano","volume":"13 ","pages":"Article 100171"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Strategies for lipid-based nanocomposites with potential activity against Mycobacterium tuberculosis: Microbial resistance challenge and drug delivery trends\",\"authors\":\"Arthur Cavalcante Hatae ,&nbsp;Cesar Augusto Roque-Borda ,&nbsp;Fernando Rogério Pavan\",\"doi\":\"10.1016/j.onano.2023.100171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><em>Mycobacterium tuberculosis</em> (MTB), the causative agent of tuberculosis, stands as an immensely devastating and persistently relevant pathogen, claiming the lives of millions each year. This infectious bacterium remains a formidable global health challenge, necessitating urgent attention and comprehensive strategies to combat its profound impact on public health. MTB is a finicky bacterium that manages to sneak into macrophages and fibroblasts to avoid being eliminated. Current first-line treatments allow the control of the spread of an active MTB, but are not capable of effectively controlling when MTB is in its latent phase and struggle against MTB resistant strains. Lipid-based nanoparticles have gained significant attention in the field of tuberculosis nanotechnology treatments, owing to their compelling logical underpinnings, remarkable merits, and acknowledged demerits. These nanoparticles offer a rational approach by harnessing the unique properties of lipids, such as biocompatibility and stability, to encapsulate and protect anti-tuberculosis drugs. Their inherent ability to actively target infected macrophages holds immense promise for precise drug delivery to the infection site, enhancing therapeutic efficacy. However, it is crucial to consider potential limitations, such as the restricted payload capacity due to their small size and challenges in achieving sustained drug release. Despite these challenges, lipid-based nanotechnology represents an exciting frontier for combating drug resistance and advancing tuberculosis treatment strategies, warranting further exploration and development in this field. In addition, we emphasize the characteristics of lipid-based nanoparticles with the ability to improve the administration, stability, and dosage of these molecules. New modified systems are expected to be successful in the coming years as nanotechnology has improved various treatments in other diseases.</p></div>\",\"PeriodicalId\":37785,\"journal\":{\"name\":\"OpenNano\",\"volume\":\"13 \",\"pages\":\"Article 100171\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"OpenNano\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352952023000506\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"OpenNano","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352952023000506","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3

摘要

结核分枝杆菌(MTB)是结核病的病原体,是一种极具破坏性和持续相关的病原体,每年夺去数百万人的生命。这种传染性细菌仍然是一个巨大的全球卫生挑战,需要紧急关注并采取全面战略,以消除其对公共卫生的深刻影响。结核分枝杆菌是一种挑剔的细菌,它设法潜入巨噬细胞和成纤维细胞以避免被消灭。目前的一线治疗方法可以控制活动性结核分枝杆菌的传播,但不能有效地控制结核分枝杆菌处于潜伏期并与耐药菌株作斗争。基于脂质的纳米颗粒由于其令人信服的逻辑基础、显著的优点和公认的缺点,在结核病纳米技术治疗领域获得了极大的关注。这些纳米颗粒提供了一种合理的方法,利用脂质的独特特性,如生物相容性和稳定性,来封装和保护抗结核药物。它们固有的主动靶向感染巨噬细胞的能力为将药物精确递送到感染部位,提高治疗效果带来了巨大的希望。然而,考虑潜在的限制是至关重要的,例如由于其体积小而限制有效载荷能力以及实现持续药物释放的挑战。尽管存在这些挑战,基于脂质的纳米技术代表了对抗耐药性和推进结核病治疗策略的一个令人兴奋的前沿,值得在这一领域进一步探索和发展。此外,我们强调了脂基纳米颗粒的特性,以及改善这些分子的给药、稳定性和剂量的能力。随着纳米技术改善了其他疾病的各种治疗方法,新的改良系统有望在未来几年取得成功。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Strategies for lipid-based nanocomposites with potential activity against Mycobacterium tuberculosis: Microbial resistance challenge and drug delivery trends

Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, stands as an immensely devastating and persistently relevant pathogen, claiming the lives of millions each year. This infectious bacterium remains a formidable global health challenge, necessitating urgent attention and comprehensive strategies to combat its profound impact on public health. MTB is a finicky bacterium that manages to sneak into macrophages and fibroblasts to avoid being eliminated. Current first-line treatments allow the control of the spread of an active MTB, but are not capable of effectively controlling when MTB is in its latent phase and struggle against MTB resistant strains. Lipid-based nanoparticles have gained significant attention in the field of tuberculosis nanotechnology treatments, owing to their compelling logical underpinnings, remarkable merits, and acknowledged demerits. These nanoparticles offer a rational approach by harnessing the unique properties of lipids, such as biocompatibility and stability, to encapsulate and protect anti-tuberculosis drugs. Their inherent ability to actively target infected macrophages holds immense promise for precise drug delivery to the infection site, enhancing therapeutic efficacy. However, it is crucial to consider potential limitations, such as the restricted payload capacity due to their small size and challenges in achieving sustained drug release. Despite these challenges, lipid-based nanotechnology represents an exciting frontier for combating drug resistance and advancing tuberculosis treatment strategies, warranting further exploration and development in this field. In addition, we emphasize the characteristics of lipid-based nanoparticles with the ability to improve the administration, stability, and dosage of these molecules. New modified systems are expected to be successful in the coming years as nanotechnology has improved various treatments in other diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
OpenNano
OpenNano Medicine-Pharmacology (medical)
CiteScore
4.10
自引率
0.00%
发文量
63
审稿时长
50 days
期刊介绍: OpenNano is an internationally peer-reviewed and open access journal publishing high-quality review articles and original research papers on the burgeoning area of nanopharmaceutics and nanosized delivery systems for drugs, genes, and imaging agents. The Journal publishes basic, translational and clinical research as well as methodological papers and aims to bring together chemists, biochemists, cell biologists, material scientists, pharmaceutical scientists, pharmacologists, clinicians and all others working in this exciting and challenging area.
期刊最新文献
Fundamentals behind the success of nanotechnology in cancer treatment and diagnosis Cellular viability in an in vitro model of human ventricular cardiomyocytes (RL-14) exposed to gold nanoparticles biosynthesized using silk fibroin from silk fibrous waste Fabrication of pyrroloquinoline quinone-loaded small unilamellar vesicles through various downsizing techniques for biomedical applications A recent advances in antimicrobial activity of green synthesized selenium nanoparticle The effect of coating chitosan from cuttlefish bone (Sepia Sp.) on the surface of orthodontic mini-screw
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1